BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich’s ataxia will be featured in two upcoming poster presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, which is taking place May 26 – 28, 2022 at the Hyatt Regency Miami in Miami, Florida.
Details on the poster presentations are shown below.
| Title: | Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia |
| Abstract Number: | 9 |
| Poster Category: | Clinical Trials and Pharmacology |
| Presenting Author: | Russell G. Clayton, D.O., Principal, Aeremedea LLC |
| Presentation Date: | May 26, 2022 |
| Presentation Time: | 1:00 – 2:30 PM ET |
| Title: | Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Dose Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia |
| Abstract Number: | 10 |
| Poster Category: | Clinical Trials and Pharmacology |
| Presenting Author: | Russell G. Clayton, D.O., Principal, Aeremedea LLC |
| Presentation Date: | May 26, 2022 |
| Presentation Time: | 1:00 – 2:30 PM ET |
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
| Investor Contact: | Company Contact: |
| Joyce Allaire | Michael Celano |
| LifeSci Advisors | Chief Financial Officer |
| jallaire@lifesciadvisors.com | mcelano@larimartx.com |
| (212) 915-2569 | (484) 414-2715 |
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…
Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…
CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…
MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…